Jianjin Xu

United States Food and Drug Administration

Also affiliated with Center for Drug Evaluation and Research

MedicineMathematicsDecision Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations”.

False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations

JCO Precision Oncology(2024)10.1200/po.24.00354

N/A

0DataRank · unranked

2 citations

Jianjin Xu, Hee‐Koung Joeng, Chana Weinstock, Brian L. Heiss, William F. Maguire +10 more